Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d14d4339984af7e821ca05dea061b8d1 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2021-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd9b77493b4de492335817fd6847c166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aa54f6554b499e4e5eddc857df4d97e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed9b3ee9a389aed59c17d86397aac1b4 |
publicationDate |
2021-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2021324082-A1 |
titleOfInvention |
Pd-l1 targeting molecules comprising shiga toxin a subunit scaffolds |
abstract |
Provided herein are PD-L1 binding molecules comprising Shiga toxin A Subunit derived polypeptides and methods of using the same. Certain PD-L1 targeting molecules embodiments are cytotoxic. Certain PD-L1 targeting molecules embodiments exhibit reduced immunogenic potential in mammals and/or are capable of delivering an immunogenic epitope to an MHC class I molecule of a PD-L1 positive cell. Certain PD-L1 targeting molecules embodiments are well-tolerated by mammals while retaining one or more of the features mentioned above. The PD-L1 targeting molecules have uses for selectively killing specific cells (e.g., PD-L1 positive tumor and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor and/or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells. |
priorityDate |
2020-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |